These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 33428528)
1. Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol. Marshall HS; Andraweera PH; Wang B; McMillan M; Koehler AP; Lally N; Almond S; Denehy E; A'Houre M; Giles LC; Flood L Hum Vaccin Immunother; 2021 May; 17(5):1450-1454. PubMed ID: 33428528 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492 [TBL] [Abstract][Full Text] [Related]
3. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation. Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Ahoure M; Denehy E; Flood L; Marshall H J Infect; 2023 Aug; 87(2):95-102. PubMed ID: 37268223 [TBL] [Abstract][Full Text] [Related]
4. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol. Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957 [TBL] [Abstract][Full Text] [Related]
5. An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study Protocol. Marshall HS; Andraweera PH; Ward J; Kaldor J; Andrews R; Macartney K; Richmond P; Krause V; Koehler A; Whiley D; Giles L; Webby R; D'Antoine H; Karnon J; Baird R; Lawrence A; Petousis-Harris H; De Wals P; Greenwood-Smith B; Binks M; Whop L Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214767 [TBL] [Abstract][Full Text] [Related]
6. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
7. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile. Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520 [TBL] [Abstract][Full Text] [Related]
8. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Marshall HS; Lally N; Flood L; Phillips P Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501 [TBL] [Abstract][Full Text] [Related]
9. Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California. Bruxvoort KJ; Lewnard JA; Chen LH; Tseng HF; Chang J; Veltman J; Marrazzo J; Qian L Clin Infect Dis; 2023 Feb; 76(3):e1341-e1349. PubMed ID: 35642527 [TBL] [Abstract][Full Text] [Related]
10. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD; BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030 [TBL] [Abstract][Full Text] [Related]
11. Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK. Ladhani SN; White PJ; Campbell H; Mandal S; Borrow R; Andrews N; Bhopal S; Saunders J; Mohammed H; Drisdale-Gordon L; Callan E; Sinka K; Folkard K; Fifer H; Ramsay ME Lancet Infect Dis; 2024 Sep; 24(9):e576-e583. PubMed ID: 38521080 [TBL] [Abstract][Full Text] [Related]
12. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Rappuoli R; Pizza M; Masignani V; Vadivelu K Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407 [TBL] [Abstract][Full Text] [Related]
13. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156 [TBL] [Abstract][Full Text] [Related]
14. Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents. McMillan M; Wang B; Koehler AP; Sullivan TR; Marshall HS Clin Infect Dis; 2021 Jul; 73(1):e233-e237. PubMed ID: 33587122 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children. Castilla J; García Cenoz M; Abad R; Sánchez-Cambronero L; Lorusso N; Izquierdo C; Cañellas Llabrés S; Roig J; Malvar A; González Carril F; Boone ALD; Pérez Martín J; Rodríguez Recio MJ; Galmés A; Caballero A; García Rojas A; Juanas F; Nieto M; Viloria Raymundo LJ; Martínez Ochoa E; Rivas AI; Castrillejo D; Moreno Pérez D; Martínez A; Borràs E; Sánchez Gómez A; Pastor E; Nartallo V; Arteagoitia JM; Álvarez-Fernández B; García Pina R; Fernández Arribas S; Vanrell J; García Hernández S; Mendoza RM; Méndez M; López-Tercero MM; Fernández-Rodríguez Á; Blanco Á; Carrillo de Albornoz FJ; Ruiz Olivares J; Ruiz-Montero R; Limia A; Navarro-Alonso JA; Vázquez JA; Barricarte A N Engl J Med; 2023 Feb; 388(5):427-438. PubMed ID: 36724329 [TBL] [Abstract][Full Text] [Related]
16. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices. Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol. Marshall H; Ward J; Wang B; Andraweera P; McMillan M; Flood L; Bell C; Sisnowski J; Krause V; Webby R; Childs E; Gunathilake M; Egoroff N; Leong L; Lawrence A; Baird R; Freeman K; Menouhos D; Whiley DM; Karnon J; van Hal S; Lahra MM BMJ Open; 2024 May; 14(5):e079144. PubMed ID: 38719318 [TBL] [Abstract][Full Text] [Related]
18. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage. Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280 [TBL] [Abstract][Full Text] [Related]
19. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB). Marshall GS; Abbing-Karahagopian V; Marshall HS; Cenci S; Conway JH; Occhipinti E; Bekkat-Berkani R; Banzhoff A; Sohn WY Expert Rev Vaccines; 2023; 22(1):530-544. PubMed ID: 37278390 [TBL] [Abstract][Full Text] [Related]
20. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. Régnier SA; Huels J Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]